- authorisedTherapeutic exploratory (Phase II)
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)
This study looks at a targeted medicine called sacituzumab govitecan for people with cancer of unknown primary (CUP). It compares this new drug against standard chemotherapy to see if it helps keep the cancer under control for longer in people whose previous treatments have stopped working.
Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
This study looks at a new treatment for solid tumours, which are common types of cancer. It uses a patient's own immune cells, called TILs, to fight the cancer. Researchers want to see how well these cells work at shrinking tumours and keeping the cancer away.
Spain · Germany · Greece - enrolling by invitation
Retrospective WGS Study
This study looks back at records of children and young people with cancer who had a special genetic test called whole genome sequencing. The aim is to see if this test helped doctors choose better treatments for them, to understand its benefits.
United Kingdom - not yet recruitingPHASE1
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
This study looks at a new drug called ceralasertib for certain cancers. It aims to understand how the body uses and removes the drug, and how much of it gets into the bloodstream. Participants will stay in hospital for parts of the study.
United Kingdom